Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of FG-4592 in maintaining
and/or correcting hemoglobin (Hb) given to subjects with End Stage Renal Disease (ESRD) on
maintenance hemodialysis and receiving epoetin alfa.
Phase:
Phase 2
Details
Lead Sponsor:
FibroGen
Collaborators:
Chang Zheng Hospital First Affiliated Hospital of Zhejiang University First Affiliated Hospital, Sun Yat-Sen University Peking Union Medical College Hospital Peking University First Hospital RenJi Hospital Ruijin Hospital Shenzhen People's Hospital Xinhua Hospital, Shanghai Jiao Tong University School of Medicine